Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
1997-4-4
|
| pubmed:abstractText |
We have developed a competitor-based RT-PCR technique which will detect and quantitate the CBFbeta/MYH11 transcripts associated with inv(16)(q22;p13) and have used it to study presentation and follow-up samples of acute myeloid leukaemia (AML). The levels of the leukaemia-specific transcripts are expressed as a ratio to a ubiquitously expressed mRNA species (Abl) which controls for RNA degradation. This technique has been applied to 75 consecutive patients presenting with either de novo AML or tMDS; 6/75 patients analysed were positive for the inv(16), all were confirmed by conventional cytogenetics. The inv(16) has a strong association with M4Eo, but we found only 2/6-positive patients to have this diagnosis (two patients with M2, one patient M1 and one patient had MDS). At presentation the levels of CBFbeta/MYH11 transcripts were 0.1-10/Abl transcript (mean 3.3/Abl transcript). Seventeen follow-up samples were available on 5/6 of these patients, and on two further patients in whom stored material was available. Following the first cycle of chemotherapy the level of transcripts was at least 10(-2) lower (0.1-10 x 10(-2)/abl transcript) than their presentation sample. Subsequent samples on these patients when in remission gave transcript levels in the range (1.0 x 10(-4) - 2 x 10(-3)/abl transcript), and three long-term follow-up samples were negative. We have developed a quantitative test which opens the possibility of predicting relapse by detecting changes in the numbers of leukaemia-specific transcripts.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
0887-6924
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
11
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
364-9
|
| pubmed:dateRevised |
2009-11-19
|
| pubmed:meshHeading |
pubmed-meshheading:9067575-Acute Disease,
pubmed-meshheading:9067575-Adult,
pubmed-meshheading:9067575-Aged,
pubmed-meshheading:9067575-Child,
pubmed-meshheading:9067575-Chromosome Inversion,
pubmed-meshheading:9067575-Chromosomes, Human, Pair 16,
pubmed-meshheading:9067575-Female,
pubmed-meshheading:9067575-Follow-Up Studies,
pubmed-meshheading:9067575-Humans,
pubmed-meshheading:9067575-Leukemia, Myeloid,
pubmed-meshheading:9067575-Male,
pubmed-meshheading:9067575-Middle Aged,
pubmed-meshheading:9067575-Oncogene Proteins, Fusion,
pubmed-meshheading:9067575-Polymerase Chain Reaction,
pubmed-meshheading:9067575-Transcription, Genetic
|
| pubmed:year |
1997
|
| pubmed:articleTitle |
Detection and quantitation of the CBFbeta/MYH11 transcripts associated with the inv(16) in presentation and follow-up samples from patients with AML.
|
| pubmed:affiliation |
Molecular Oncology, The General Infirmary at Leeds, West Yorkshire, UK.
|
| pubmed:publicationType |
Journal Article
|